

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

SAFETY DATA SHEET

FRS-40 SEMI-GLOSS BASE GREY METAL FS27178

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

Product name SDS code : FRS-40 SEMI-GLOSS BASE GREY METAL FS27178 : 409Z7178B

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses		
Paint. Professional use Industrial use		
Uses advised against		
All other uses		
Product use	: Solvent borne coating for interior use.	

1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

1.4 Emergency telephone number

responsible for this SDS

National advisory body/Poison Center		
: +33 (0)1 40 05 48 48		
: +33 (0)5 34 01 34 01		
+33 (0)5 61 60 23 30		
:		

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H336

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

Date of issue/Date of revision	: 1-10-2022	Version :1	
Date of previous issue	: No previous validation	1/23	AkzoNobel

SECTION 2: Hazards identification


2.2 Label elements

Hazard pictograms

Hazard statements

Signal word

Disposal



- Prevention : Obtain special instructions before use. Wear protective gloves, protective clothing and eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Avoid breathing vapor. : IF exposed or concerned: Get medical advice or attention. IF INHALED: Call a Response
- POISON CENTER or doctor if you feel unwell. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention. : Store in a well-ventilated place. Keep container tightly closed. Keep cool. Storage
 - : Dispose of contents and container in accordance with all local, regional, national
- and international regulations. **Hazardous ingredients** : n-butyl acetate
 - 4-methylpentan-2-one
- Supplemental label : Contains methyl methacrylate and 4-morpholinecarbaldehyde. May produce an elements allergic reaction. Repeated exposure may cause skin dryness or cracking.
- **Annex XVII Restrictions** : Not applicable. on the manufacture.
- placing on the market and use of certain dangerous substances, mixtures and articles

Special packaging requirements

- Containers to be fitted : Not applicable. with child-resistant fastenings Tactile warning of danger : Not applicable.
- 2.3 Other hazards

Product meets the criteria	: This mixture does not contain any substances that are assessed to be a PBT or a
for PBT or vPvB according	vPvB.
to Regulation (EC) No.	
1907/2006. Annex XIII	

1907/20 Other hazards which do : None known. not result in classification



SECTION 3: Composition/information on ingredients

3.2 Mixtures : Product/ingredient name	Mixture Identifiers	%	Regulation (EC) No.	Туре
			1272/2008 [CLP]	
n-butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1	≥25 - ≤50	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	[1] [2]
2-methoxy-1-methylethyl acetate	REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6	≥10 - ≤25	Flam. Liq. 3, H226 STOT SE 3, H336	[1] [2]
Reaction mass of ethylbenzene and xylene	REACH #: 01-2119488216-32 EC: 905-588-0	<10	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
4-methylpentan-2-one	EC: 203-550-1 CAS: 108-10-1 Index: 606-004-00-4	≤5	Flam. Liq. 2, H225 Acute Tox. 4, H332 Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H336 EUH066	[1] [2]
ethyl acetate	REACH #: 01-2119475103-46 EC: 205-500-4 CAS: 141-78-6 Index: 607-022-00-5	≤3	Flam. Liq. 2, H225 Eye Irrit. 2, H319 STOT SE 3, H336 EUH066	[1] [2]
isopropyl acetate	REACH #: 01-2119537214-46 EC: 203-561-1 CAS: 108-21-4 Index: 607-024-00-6	<1	Flam. Liq. 2, H225 Eye Irrit. 2, H319 STOT SE 3, H336 EUH066	[1] [2]
methyl methacrylate	REACH #: 01-2119452498-28 EC: 201-297-1 CAS: 80-62-6 Index: 607-035-00-6	<1	Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335	[1] [2]
4-morpholinecarbaldehyde	EC: 224-518-3 CAS: 4394-85-8	<1	Skin Sens. 1, H317	[1]
cyclohexanone	REACH #: 01-2119453616-35 EC: 203-631-1 CAS: 108-94-1 Index: 606-010-00-7	≤0.1	Flam. Liq. 3, H226 Acute Tox. 4, H332	[1] [2]
cumene	REACH #: 01-2119473983-24 EC: 202-704-5 CAS: 98-82-8 Index: 601-024-00-X	≤0.1	Flam. Liq. 3, H226 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 2, H411 See Section 16 for the full text of the H statements declared	[1] [2]

Date of issue/Date of revision Date of previous issue : 1-10-2022 : No previous validation Version :1

3/23



SECTION 3: Composition/information on ingredients

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Туре

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
- [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
- [5] Substance of equivalent concern
- [6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Skin contact	: Wash skin thoroughly with soap and water or use recognized skin cleanser. Remove contaminated clothing and shoes. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	: Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Date of issue/Date of revision	: 1-10-2022	Version : 1	
Date of previous issue	: No previous validation	4/23	AkzoNobel

SECTION 4: First aid measures

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains methyl methacrylate, 4-morpholinecarbaldehyde. May produce an allergic reaction.

Over-exposure signs/symptoms

Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation dryness cracking
Ingestion	No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	 Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments	: No specific treatment.

SECTION 5: Firefighting measures

•	•
5.1 Extinguishing media	
Suitable extinguishing media	: Use dry chemical, CO ₂ , water spray (fog) or foam.
Unsuitable extinguishing media	: Do not use water jet.
5.2 Special hazards arising f	rom the substance or mixture
Hazards from the substance or mixture	: Flammable liquid and vapor. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion.
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide metal oxide/oxides
5.3 Advice for firefighters	
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.



SECTION 6: Accidental release measures

6.1 Personal precautions, pro	ote	ctive equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and materials for	r c	ontainment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.
6.4 Reference to other sections	:	See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapor or mist. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

SECTION 7: Handling and storage

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Seveso Directive - Reporting thresholds

Danger criteria

	Notification and MAPP threshold	Safety report threshold
P5c	5000 tonne	50000 tonne

7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific	: Not available.

Industrial sector specific solutions

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

Product/ingredien	t name	Exposure limit values				
n-butyl acetate		Ministry of Labor (France, 3/2020). Notes: In values (circular) STEL: 940 mg/m ³ 15 minutes. Form: Risk for STEL: 200 ppm 15 minutes. Form: Risk for se TWA: 710 mg/m ³ 8 hours. Form: Risk for sen TWA: 150 ppm 8 hours. Form: Risk for sensit	sensitisation ensitisation sitisation			
2-methoxy-1-methylethyl aceta	ate	Ministry of Labor (France, 10/2016). Absorbed through skin. Notes: Labour Act , Art 4412-149 (Regulatory binding exposure limits) STEL: 550 mg/m ³ 15 minutes. STEL: 100 ppm 15 minutes. TWA: 275 mg/m ³ 8 hours. TWA: 50 ppm 8 hours.				
Reaction mass of ethylbenzen	e and xylene	Ministry of Labor (France, 3/2020). Absorber Notes: Binding regulatory limit values (artic the Labor Code) STEL: 442 mg/m ³ 15 minutes. Form: Risk for STEL: 100 ppm 15 minutes. Form: Risk for ser TWA: 221 mg/m ³ 8 hours. Form: Risk for sen TWA: 50 ppm 8 hours. Form: Risk for sensitis	le R. 4412-149 of sensitisation ensitisation sitisation			
4-methylpentan-2-one		Ministry of Labor (France, 3/2020). Notes: E limit values (article R. 4412-149 of the Labor STEL: 208 mg/m ³ 15 minutes. Form: Risk for STEL: 50 ppm 15 minutes. Form: Risk for sens TWA: 83 mg/m ³ 8 hours. Form: Risk for sensitis TWA: 20 ppm 8 hours. Form: Risk for sensitis	Binding regulatory • Code) sensitisation isitisation tisation			
ethyl acetate		Ministry of Labor (France, 3/2020). Notes: E limit values (article R. 4412-149 of the Labor TWA: 734 mg/m ³ 8 hours. Form: Risk for sen TWA: 200 ppm 8 hours. Form: Risk for sensit	Binding regulatory • Code) sitisation			
Date of issue/Date of revision	: 1-10-2022	Version :1				
Date of previous issue	: No previous va	lidation 7/23	AkzoNobel			

	WEINER BEITING
SECTION 8: Exposure controls/personal prote	ection

SECTION 0. Exposu	e controls/personal protection
	Ministry of Labor (France, 3/2020). Notes: Binding regulatory limit values (article R. 4412-149 of the Labor Code) STEL: 1468 mg/m ³ 15 minutes. STEL: 400 ppm 15 minutes.
isopropyl acetate	Ministry of Labor (France, 3/2020). Notes: Indicative limit values (circular) STEL: 1140 mg/m ³ 15 minutes. STEL: 300 ppm 15 minutes. TWA: 950 mg/m ³ 8 hours. TWA: 250 ppm 8 hours.
methyl methacrylate	Ministry of Labor (France, 3/2020). Notes: Binding regulatory limit values (article R. 4412-149 of the Labor Code) STEL: 410 mg/m ³ 15 minutes. Form: Risk for sensitisation STEL: 100 ppm 15 minutes. Form: Risk for sensitisation TWA: 205 mg/m ³ 8 hours. Form: Risk for sensitisation TWA: 50 ppm 8 hours. Form: Risk for sensitisation
cyclohexanone	Ministry of Labor (France, 3/2020). Notes: Binding regulatory limit values (article R. 4412-149 of the Labor Code) STEL: 81.6 mg/m ³ 15 minutes. Form: Risk for sensitisation STEL: 20 ppm 15 minutes. Form: Risk for sensitisation TWA: 40.8 mg/m ³ 8 hours. Form: Risk for sensitisation TWA: 10 ppm 8 hours. Form: Risk for sensitisation
cumene	Ministry of Labor (France, 3/2020). Absorbed through skin. Notes: Binding regulatory limit values (article R. 4412-149 of the Labor Code) STEL: 250 mg/m ³ 15 minutes. Form: Risk for sensitisation STEL: 50 ppm 15 minutes. Form: Risk for sensitisation TWA: 100 mg/m ³ 8 hours. Form: Risk for sensitisation TWA: 20 ppm 8 hours. Form: Risk for sensitisation
Recommended monitoring procedures	 If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

Product/ingredient na	ame Type	Exposure	Value	Population	Effects
n-butyl acetate	DNEL	Long term Oral	3.4 mg/kg bw/day	General population	Systemic
	DNEL	Long term Dermal	3.4 mg/kg bw/day	General population	Systemic
	DNEL	Long term Dermal	7 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Inhalation	12 mg/m³	General population	Systemic
	DNEL	Long term Inhalation	48 mg/m³	Workers	Systemic
	DNEL	Long term Inhalation	102.34 mg/ m ³	General population	Local
	DNEL	Long term	480 mg/m ³	Workers	Local
te of issue/Date of revision	: 1-10-2022		Version	:1	
te of previous issue	: No previous va	alidation	8/23		AkzoNobe

SECTION 8: Exposure controls/personal protection

•		personal prote	otton		
		Inhalation	050 7 /		
	DNEL	Short term	859.7 mg/	General	Local
		Inhalation	m ³	population	
	DNEL	Short term	859.7 mg/	General	Systemic
		Inhalation	m ³	population	
	DNEL	Short term	960 mg/m ³	Workers	Local
		Inhalation			
	DNEL	Short term	960 mg/m ³	Workers	Systemic
		Inhalation	J		,
Reaction mass of ethylbenzene a	nd DNEL	Long term Oral	1.6 mg/kg	General	Systemic
xylene		Long term ora	bw/day	population	Oysternie
xylene	DNEL	Long torm	14.8 mg/m ³	General	Svotomio
	DINEL	Long term	14.0 mg/m		Systemic
		Inhalation	77	population	O un tra maile
	DNEL	Long term	77 mg/m³	Workers	Systemic
		Inhalation			
	DNEL	Long term Dermal	108 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Dermal	180 mg/kg	Workers	Systemic
			bw/day		
	DNEL	Short term	289 mg/m ³	Workers	Local
		Inhalation	3		
	DNEL	Short term	289 mg/m ³	Workers	Systemic
	DITEE	Inhalation	200 mg/m	Tronkoro -	eyetenne
4-methylpentan-2-one	DNEL	Long term Oral	4.2 mg/kg	General	Systemic
4-metrypentan-z-one	DINEL	Long term Oral	bw/day		Systemic
		Long town Downed		population	Curatamia
	DNEL	Long term Dermal	4.2 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Dermal	11.8 mg/	Workers	Systemic
			kg bw/day		
	DNEL	Long term	14.7 mg/m ³		Local
		Inhalation		population	
	DNEL	Long term	14.7 mg/m ³	General	Systemic
		Inhalation		population	
	DNEL	Long term	83 mg/m³	Workers	Local
		Inhalation	ee		
	DNEL	Long term	83 mg/m³	Workers	Systemic
	DINEE	Inhalation	oo mg/m	Wonters	Gysterino
	DNEL	Short term	155.2 mg/	General	Local
	DINEL	Inhalation	m ³		LUCAI
				population	Curatamia
	DNEL	Short term	155.2 mg/	General	Systemic
		Inhalation	m ³	population	
	DNEL	Short term	208 mg/m ³	Workers	Local
		Inhalation			
	DNEL	Short term	208 mg/m ³	Workers	Systemic
		Inhalation			
ethyl acetate	DNEL	Long term Oral	4.5 mg/kg	General	Systemic
-		-	bw/day	population	-
	DNEL	Long term Dermal	37 mg/kg	General	Systemic
		J	bw/day	population	,
	DNEL	Long term Dermal	63 mg/kg	Workers	Systemic
		Long term Derma	bw/day	WOINEI3	Cysternic
	DNEL	Long torm		General	
	DINEL	Long term	367 mg/m ³	General	Local
		Inhalation	007	population	Quarter
	DNEL	Long term	367 mg/m ³	General	Systemic
		Inhalation		population	
	DNEL	Short term	734 mg/m ³	General	Local
		Inhalation		population	
	DNEL	Short term	734 mg/m³	General	Systemic
		Inhalation	_	population	
	DNEL	Long term	734 mg/m ³	Workers	Local
		Inhalation			
			•		
	DNEL		734 ma/m ³	Workers	Systemic
	DNEL	Long term	734 mg/m ³	Workers	Systemic
e of issue/Date of revision :	DNEL		734 mg/m ³ Version	Workers	
		Long term	-		Systemic AkzoNob

SECTION 8: Exposure controls/personal protection

			10/23		AkzoNobe
e of issue/Date of revision	: 1-10-2022	l	Version	: 1	l
	DNEL	Inhalation Short term	20 mg/m³	population General	Systemic
	DNEL	Long term	20 mg/m³	General	Local
	DNEL	Long term Inhalation	10 mg/m ³	General population	Systemic
	DNEL	Long term Dermal	4 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Dermal	4 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Oral	1.5 mg/kg bw/day	General population	Systemic
	DNEL	Short term Oral	1.5 mg/kg bw/day	General population	Systemic
	DNEL	Long term Dermal	1 mg/kg bw/day	General population	Systemic
cyclohexanone	DNEL	Short term Dermal	1 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	98 mg/m³	Workers	Systemic
	DNEL	Long term Inhalation	29 mg/m ³	General population	Systemic
	DNEL	Long term Dermal	bw/day 14 mg/kg bw/day	population Workers	Systemic
	DNEL	Long term Dermal	bw/day 8 mg/kg	population General	Systemic
1-morpholinecarbaldehyde	DNEL	Inhalation Long term Oral	8 mg/kg	General	Systemic
	DNEL	Inhalation Long term	208 mg/m ³	Workers	Systemic
	DNEL	Inhalation Long term	208 mg/m ³	population Workers	Local
	DNEL	Inhalation Long term	104 mg/m³	population General	Local
	DNEL	Long term	kg bw/day 74.3 mg/m³	General	Systemic
	DNEL	Long term Dermal	bw/day 13.67 mg/	population Workers	Systemic
nethyl methacrylate	DNEL	Inhalation Long term Dermal	8.2 mg/kg	General	Systemic
	DNEL	Inhalation Short term	850 mg/m³	population Workers	Systemic
	DNEL	Inhalation Short term	510 mg/m ³	General	Systemic
	DNEL	Inhalation Long term	420 mg/m ³	Workers	Systemic
	DNEL	Inhalation Long term	420 mg/m³	population Workers	Local
	DNEL	Inhalation Long term	252 mg/m ³	population General	Systemic
	DNEL	Long term	bw/day 252 mg/m³	General	Local
	DNEL	Long term Dermal	bw/day 43 mg/kg	population Workers	Systemic
	DNEL	Long term Dermal	bw/day 26 mg/kg	population General	Systemic
sopropyl acetate	DNEL	Inhalation Long term Oral	m ³ 26 mg/kg	General	Systemic
	DNEL	Inhalation Short term	m³ 1468 mg/	Workers	Systemic
	DNEL	Short term	1468 mg/	Workers	Local

SECTION	8:	Exposure	contro	s/pe	rsonal	protection

SECTION 6: Exposure con	1015/h	ersonal prote	cuon		
		Inhalation		population	
	DNEL	Short term	40 mg/m³	General	Local
		Inhalation		population	
	DNEL	Long term	40 mg/m³	Workers	Local
		Inhalation			
	DNEL	Long term	40 mg/m³	Workers	Systemic
		Inhalation	aa / 3	147	
	DNEL	Short term	80 mg/m³	Workers	Local
		Inhalation	00		Overte main
	DNEL	Short term Inhalation	80 mg/m³	Workers	Systemic
cumene	DNEL	Long term Dermal	1.2 mg/kg	General	Systemic
Cumene		Long term Derma	bw/day	population	Oysternic
	DNEL	Long term Oral	5 mg/kg	General	Systemic
			bw/day	population	-)
	DNEL	Long term Dermal	15.4 mg/	Workers	Systemic
		0	kg bw/day		5
	DNEL	Long term	16.6 mg/m ³	General	Systemic
		Inhalation		population	
	DNEL	Long term	100 mg/m³	Workers	Systemic
		Inhalation			
	DNEL	Short term	250 mg/m ³	Workers	Local
		Inhalation			

PNECs

No PNECs available.

8.2 Exposure controls

Appropriate engineering controls	:	Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapor or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment
		explosive limits. Use explosion-proof ventilation equipment.

Individual protection measures

Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.
Skin protection	
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.



SECTION 8: Exposure controls/personal protection

I	• •
	When prolonged or frequently repeated contact may occur, a glove with a protection class of 6 (breakthrough time >480 minutes according to EN374) is recommended. Recommended gloves: Viton ® or Nitrile, thickness \geq 0.38 mm. When only brief contact is expected, a glove with protection class of 2 or higher (breakthrough time >30 minutes according to EN374) is recommended. Recommended gloves: Nitrile, thickness \geq 0.12 mm. Gloves should be replaced regularly and if there is any sign of damage to the glove material.
	The performance or effectiveness of the glove may be reduced by physical/ chemical damage and poor maintenance.
	The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Date of previous issue	: No previous validation	12/23	AkzoNobe
Date of issue/Date of revision	: 1-10-2022	Version : 1	
Solubility(ies)	: Insoluble in the following n	naterials: cold water.	
Density	: 0.977 g/cm ³		
Vapor density	: Highest known value: 4.6 Weighted average: 4.02 ((Air = 1) (2-methoxy-1-meth Air = 1)	ylethyl acetate).
Vapor pressure	: Not available.		
Upper/lower flammability or explosive limits	: Not available.		
Flammability (solid, gas)	: Not available.		
Evaporation rate	: Not available.		
Flash point	: Closed cup: 28°C		
Initial boiling point and boiling range	: Not available.		
Melting point/freezing point	: Not available.		
рН	: Not available.		
Odor threshold	: Not available.		
Odor	: Characteristic.		
Color	: Silver.		
Physical state	: Liquid.		
<u>Appearance</u>			

SECTION 9: Physical and chemical properties

Partition coefficient: n-octanol/ water	:	Not available.
Auto-ignition temperature	:	Not available.
Decomposition temperature	:	Not available.
Viscosity	:	Kinematic (room temperature): 11.26 cm²/s Kinematic (40°C): 1.01 cm²/s

SECTION 10: Stabilit	y and reactivity
10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.
10.5 Incompatible materials	: Reactive or incompatible with the following materials: oxidizing materials
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
n-butyl acetate	LC50 Inhalation Gas.	Rat	390 ppm	4 hours
	LC50 Inhalation Vapor	Mouse	6 g/m ³	2 hours
	LD50 Dermal	Rabbit	>17600 mg/kg	-
	LD50 Intraperitoneal	Mouse	1230 mg/kg	-
	LD50 Oral	Guinea pig	4700 mg/kg	-
	LD50 Oral	Mouse	6 g/kg	-
	LD50 Oral	Rabbit	3200 mg/kg	-
	LD50 Oral	Rat	10768 mg/kg	-
Reaction mass of	LC50 Inhalation Gas.	Rat	5000 ppm	4 hours
ethylbenzene and xylene				
4-methylpentan-2-one	LD50 Intraperitoneal	Guinea pig	800 mg/kg	-
	LD50 Intraperitoneal	Mouse	268 mg/kg	-
	LD50 Intraperitoneal	Rat	400 mg/kg	-
	LD50 Oral	Guinea pig	1600 mg/kg	-
	LD50 Oral	Mouse	1900 mg/kg	-
	LD50 Oral	Mouse	2850 mg/kg	-
	LD50 Oral	Rat	2080 mg/kg	-
	LD50 Oral	Rat	4600 mg/kg	-
ethyl acetate	LC50 Inhalation Gas.	Rat	1600 ppm	8 hours
-	LC50 Inhalation Vapor	Mouse	45 g/m ³	2 hours
	LD50 Intraperitoneal	Mouse	709 mg/kg	-
	LD50 Oral	Guinea pig	5.5 g/kg	-
	LD50 Oral	Guinea pig	5500 mg/kg	-
	LD50 Oral	Mouse	4.1 g/kg	-
	LD50 Oral	Mouse	4100 mg/kg	-
e of issue/Date of revision	: 1-10-2022	 Version	<u>ו</u> ז :1	<u> </u>
e of previous issue	: No previous validation	13/23		AkzoNob

SECTION 11: Toxicological information

Isopropyl acetateLD50 Oral LD50 Subcutaneous LC50 Inhalation Vapor LC50 Inhalation Vapor RatRabit Rat6946 mg/kg 6946 mg/kg 9780 mg/kgmethyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhalation Vapor LD50 OralRat6946 mg/kg 9780 mg/kg-methyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 OralMouse18500 mg/m³ 2 hoursMouseSeg /kg 1000 mg/m³-LC50 Intraperitoneal LD50 OralRat78000 mg/m³ 2 hoursLD50 Intraperitoneal LD50 Intraperitoneal LD50 OralRat7800 mg/kg 2 hoursLD50 Oral LD50 Oral LD50 OralRat7870 mg/kg 2 hours4-morpholinecarbaldehyde cyclohexanoneColineapic LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperitoneal Rati110L/kg RaticumeneLC50 Inhalation Vapor LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal Rati1100 mg/kg RaticumeneLC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhala		ogioar information			
isopropyl acetateLD50 Subcutaneous LC50 Inhalation Vapor LD50 OralGuinea pig Rat3 g/kg-methyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhalation VaporRat6946 mg/kg 6750 mg/kg-methyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LD50 DermalRat78000 mg/m³4 hoursBabbit>5 g/kgLD50 Intraperitoneal LD50 IntraperitonealGuinea pig LD50 Intraperitoneal1890 mg/kg Rat-LD50 Oral LD50 OralMouse3625 mg/kg SMg/kg-LD50 Subcutaneous LD50 OralGuinea pig LD50 Oral5954 mg/kg Rg-LD50 Subcutaneous LD50 SubcutaneousGuinea pig S954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousGuinea pig S954 mg/kg Rg-4-morpholinecarbaldehyde cyclohexanoneLD50 Intraperitoneal LD50 IntraperitonealRat Rat7708 mg/kg Rg-LD50 Intraperitoneal LD50 IntraperitonealRat Rat11 mL/kgLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Rat930 mg/kg Rg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg Rg-LD50 Intraperitoneal LD50 IntraperitonealRabbit1 mL/kg-LD50 Intraperitoneal LD50 IntraperitonealRabbit1 540 mg/kg Rg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 Intraperitoneal <td></td> <td>LD50 Oral</td> <td>Rabbit</td> <td>4935 mg/kg</td> <td>-</td>		LD50 Oral	Rabbit	4935 mg/kg	-
Isopropyl acetateLD50 Subcutaneous LC50 Inhalation Vapor LD50 OralGuinea pig Rat3 g/kg-methyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhalation Vapor RatRabbit6946 mg/kg 6750 mg/kg-methyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LD50 DermalRatu Rabbit78000 mg/m³ 2 hours2 hoursLD50 Dermal LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig1890 mg/kg 554 mg/kg-LD50 Intraperitoneal LD50 OralMouse945 mg/kg 9-LD50 Oral LD50 SubcutaneousMouse3625 mg/kg 9-LD50 Subcutaneous LD50 SubcutaneousGuinea pig Guinea pig5954 mg/kg 9-4-morpholinecarbaldehyde cyclohexanoneLD50 OralRat LD50 Subcutaneous7088 mg/kg 9-LD50 Intraperitoneal LD50 SubcutaneousRat B000 pg/mg5954 mg/kg 9-LD50 Subcutaneous LD50 SubcutaneousRat Rat7088 mg/kg 9-LD50 Intraperitoneal LD50 IntraperitonealRat Rat100 pg/mg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig 930 mg/kgLD50 Intraperitoneal LD50 IntraperitonealRabbit Rabbit1 mL/kg-LD50 Intraperitoneal LD50 IntraperitonealRabbit Rabbit1 mL/kg-LD50 Intraperitoneal LD50 IntraperitonealRabbit Rabbit1 S40 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat Rabbit		LD50 Oral	Rat	5620 mg/kg	-
isopropyl acetateLC50 Inhalation Vapor LD50 OralRat50800 mg/kg8 hoursmethyl methacrylateLC50 Inhalation Vapor LC50 Inhalation VaporRat6750 mg/kg-methyl methacrylateLC50 Inhalation Vapor LD50 DermalRat78000 mg/m³2 hoursLC50 Inhalation Vapor LD50 DermalRat750 g/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig1980 mg/kg-LD50 Intraperitoneal LD50 OralGuinea pig Guinea pig5954 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Oral LD50 SubcutaneousRat7872 mg/kg-LD50 Subcutaneous LD50 SubcutaneousGuinea pig Rat5954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Dermal LD50 SubcutaneousRat7088 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat8000 ppm4 hoursLD50 Intraperitoneal LD50 IntraperitonealRabbit1 mL/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRabbit1 mL/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1300 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1300 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-		LD50 Subcutaneous	Guinea pig	3 g/kg	-
ImageLD50 Oral LC50 Inhalation Vapor LC50 Inhalation Vapor RatRat6750 mg/kg 1800 mg/m32 hours2 hoursLC50 Inhalation Vapor LD50 Dermal LD50 Intraperitoneal LD50 IntraperitonealRabbit>5 g/kg 945 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse Guinea pig 5954 mg/kgLD50 Oral LD50 OralGuinea pig Guinea pig 5954 mg/kgLD50 Oral LD50 OralMouse Guinea pig 5954 mg/kgLD50 Oral LD50 OralMouse Rabbit8700 mg/kg 8700 mg/kg-LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous Rat6500 uL/kg 7028 mg/kg-CyclohexanoneLD50 Oral LD50 Intraperitoneal LD50 Subcutaneous LD50 Intraperitoneal RatRat6500 uL/kg 7028 mg/kg-LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal Rabit1 mL/kg 700 mg/kg-CumeneLD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal RabitRat1130 mg/kg 700 mg/kg-CumeneLC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhalation VaporRat1130 mg/kg 700 mg/kg-CumeneLC50 Inhalation Vapor LC50 Inhalation VaporMouse10000 mg/m3 7 hours7 hours 7 hoursCumeneLC50 Inhalation Vapor LC50 Inhalation VaporMouse10000	isopropyl acetate	LC50 Inhalation Vapor			8 hours
LD50 OralRat6750 mg/kg-methyl methacrylateLC50 Inhalation VaporRat78000 mg/m32 hoursLC50 Inhalation VaporRat78000 mg/m34 hoursLD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRat7727 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg- <td></td> <td>LD50 Oral</td> <td>Rabbit</td> <td>6946 mg/kg</td> <td>-</td>		LD50 Oral	Rabbit	6946 mg/kg	-
methyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhalation Vapor RatMouse18500 mg/m³ rst 2 hours2 hours thoursLC50 Intraperitoneal LD50 IntraperitonealRabit>5 g/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse945 mg/kg-LD50 Intraperitoneal LD50 OralGuinea pig Guinea pig5954 mg/kg-LD50 Oral LD50 OralGuinea pig LD50 Oral5954 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Subcutaneous LD50 SubcutaneousGuinea pig S954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousMouse5954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Dermal LD50 IntraperitonealRabbit1 mL/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRabbit1 mL/kg-LD50 Intraperitoneal LD50 IntraperitonealRabit1540 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Oral LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRabit1540 mg/kg-LD50 Intraperitoneal LD50 OralRat1800 mg/kg-LD50 Oral LD50 OralRat1800 mg/kg-LD50		LD50 Oral	Rat		-
LC50Inhalation Vapor LD50Rat78000 mg/m34 hoursLD50DermalRabbit>5 g/kg-LD50IntraperitonealGuinea pig UD501890 mg/kg-LD50IntraperitonealMouse945 mg/kg-LD50IntraperitonealRat1328 mg/kg-LD50OralGuinea pig UD505954 mg/kg-LD50OralMouse3625 mg/kg-LD50OralRat7872 mg/kg-LD50OralRat7872 mg/kg-LD50SubcutaneousGuinea pig UD50 Subcutaneous5954 mg/kg-LD50SubcutaneousRat7088 mg/kg-LD50SubcutaneousRat6500 uL/kg-LD50IntraperitonealRat6500 uL/kg-LD50IntraperitonealGuinea pig US00 mg/kg930 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealRabbit1540 mg/kg-LD50IntraperitonealRabbit1540 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg	methyl methacrylate	LC50 Inhalation Vapor	Mouse	18500 mg/m ³	2 hours
LD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 DermalRat6500 uL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg </td <td></td> <td></td> <td>Rat</td> <td>78000 mg/m³</td> <td>4 hours</td>			Rat	78000 mg/m ³	4 hours
LD50Intraperitoneal LD50Guinea pig Mouse1890 mg/kg 945 mg/kg-LD50Intraperitoneal LD50Rat1328 mg/kg-LD50Oral LD50Guinea pig S954 mg/kgLD50Oral LD50Mouse3625 mg/kg-LD50Oral LD50Rati7872 mg/kg-LD50Subcutaneous LD50Guinea pig S954 mg/kg-LD50Subcutaneous LD50Mouse5954 mg/kg-LD50Subcutaneous LD50Mouse5954 mg/kg-LD50Subcutaneous LD50Rat6500 uL/kg-LD50Doral LD50Rat6500 uL/kg-LD50Intraperitoneal LD50Guinea pig B000 ppm4 hoursLD50Intraperitoneal LD50Mouse1230 mg/kg-LD50Intraperitoneal LD50Mouse1230 mg/kg-LD50Intraperitoneal LD50Mouse1230 mg/kg-LD50Intraperitoneal LD50Rati1130 mg/kg-LD50Intraperitoneal LD50Rati1130 mg/kg-LD50Intraperitoneal LD50Rati1130 mg/kg-LD50Intraperitoneal LD50Rati1130 mg/kg-LD50Intraperitoneal LD50Rati1130 mg/kg-LD50Intraperitoneal LD50Rati1300 mg/kg-LD50Intraperitoneal LD50Rati1300 mg/kg- <tr< td=""><td></td><td></td><td>Rabbit</td><td></td><td>-</td></tr<>			Rabbit		-
LD50Intraperitoneal LD50Mouse945 mg/kg-LD50Intraperitoneal LD50Rat1328 mg/kg-LD50OralGuinea pig5954 mg/kg-LD50OralMouse3625 mg/kg-LD50OralRabbit8700 mg/kg-LD50OralRabbit8700 mg/kg-LD50SubcutaneousGuinea pig5954 mg/kg-LD50SubcutaneousMouse5954 mg/kg-LD50SubcutaneousRat7088 mg/kg-LD50SubcutaneousRat6000 uL/kg-LD50DralRat6000 uL/kg-LD50IntraperitonealRat8000 ppm4 hoursLD50IntraperitonealRat8000 ppm4 hoursLD50IntraperitonealRat1300 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntaperitonealRat <td></td> <td>LD50 Intraperitoneal</td> <td>Guinea pig</td> <td></td> <td>-</td>		LD50 Intraperitoneal	Guinea pig		-
LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7088 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 OralRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-					-
LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 OralRat8000 ppm4 hoursLD50 DermalRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1800 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1800 mg/kgLD50 OralRat1620 uL/kgLD50 OralRat1620 uL/kgLD50 OralRat1300 mg/kgLD50 OralRat1600 mg/kgLD50 OralRat1620 uL/kgLD50 OralRat16			Rat		-
LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 OralRat6500 uL/kg-cyclohexanoneLC50 Inhalation Gas.Rat8000 ppmLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat1620 uL/kg-LD50 Inhalation VaporMouse15300 mg/m³2 hoursLD50 Inhalation VaporM			Guinea pig	5954 mg/kg	-
LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 OralRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1620 uL/kg-LD50 Oral </td <td></td> <td>LD50 Oral</td> <td></td> <td></td> <td>-</td>		LD50 Oral			-
LD50 OralRat7872 mg/kg-4-morpholinecarbaldehydeLD50 SubcutaneousMouse5954 mg/kg-cyclohexanoneLD50 OralRat7088 mg/kg-LD50 OralRat6500 uL/kg-LD50 OralRat6500 uL/kg-LD50 DoralRat8000 ppm4 hoursLD50 Inhalation Gas.Rat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LD50 SubcutaneousRat2170 mg/kg-LD50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse1000 mg/m³2 hoursLC50 Inhalation VaporMouse1000 mg/m³7 hoursLC50 Inhalation VaporMouse1000 mg/m³4 hoursLD50 DermalRa		LD50 Oral	Rabbit		-
4-morpholinecarbaldehyde cyclohexanoneLD50 Subcutaneous LD50 Subcutaneous LD50 SubcutaneousGuinea pig Mouse5954 mg/kg 5954 mg/kg-4-morpholinecarbaldehyde cyclohexanoneLD50 Oral LD50 OralRat6500 uL/kg 700 and CasLD50 Dermal LD50 DermalRat8000 ppm4 hoursLD50 Inhalation Gas. LD50 IntraperitonealRat8000 ppm4 hoursLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Mouse930 mg/kg 930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg 930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRabbit1540 mg/kg 1540 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg 9-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg 9-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg 9-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg 9-LD50 Intraperitoneal LD50 OralRat1620 uL/kg 9-LD50 Oral LD50 OralRat1620 uL/kg 9-LD50 Subcutaneous LC50 Inhalation Vapor LC50 Inhalation VaporMouse10 g/m³ 37 hoursLC50 Inhalation Vapor LC50 Inhalation VaporMouse10 g/m³ 37 hoursLC50 Inhalation Vapor LC50 Inhalation VaporMouse10 g/m³ 4 hours7 hoursLD50 Dermal LD50 Dermal LD50 OralRabbit12300 uL/kg 4 hours		LD50 Oral	Rat		-
LD50 Subcutaneous LD50 SubcutaneousMouse5954 mg/kg-4-morpholinecarbaldehyde cyclohexanoneLD50 OralRat7088 mg/kg-LD50 OralRat6500 uL/kg-LD50 DermalRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LD50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 DermalRabbit12300 uL/kg-LD50 OralRat39000 mg/m³4 hoursLD50 DormalLD50 OralRat39000 mg/m³4 hoursLD50 De		LD50 Subcutaneous	Guinea pig		-
4-morpholinecarbaldehyde cyclohexanoneLD50 Subcutaneous LD50 OralRat7088 mg/kg-4-morpholinecarbaldehyde cyclohexanoneLD50 OralRat6500 uL/kg-LC50 Inhalation Gas. LD50 DermalRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LD50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 DermalRabbit12300 uL/kg-LD50 DermalKabbit12300 uL/kg-LD50 OralMouse10000 m		LD50 Subcutaneous			-
4-morpholinecarbaldehyde cyclohexanoneLD50 OralRat6500 uL/kg-LC50 Inhalation Gas. LD50 DermalRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat1620 uL/kg-LD50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLD50 DermalRabit12300 uL/kg-LD50 DermalRabit12300 uL/kg-LD50 OralKat39000 mg/m³4 hoursLD50 DermalLD50 OralRat39000 mg/m³4 hours		LD50 Subcutaneous	Rat		-
cyclohexanoneLC50 Inhalation Gas. LD50 Dermal LD50 DermalRat8000 ppm4 hoursLD50 Dermal LD50 IntraperitonealGuinea pig Guinea pig930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRabbit1540 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 OralRat1620 uL/kg-LD50 Oral LD50 OralRat1620 uL/kg-LD50 Subcutaneous LC50 Inhalation Vapor LC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation Vapor LC50 Inhalation VaporMouse10000 mg/m³4 hoursLD50 Dermal LD50 OralRat39000 mg/m³4 hoursLD50 Dermal LD50 OralRat39000 mg/m³4 hours	4-morpholinecarbaldehyde	LD50 Oral	Rat		-
LD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 DermalRabbit12300 uL/kg-LD50 OralRat39000 mg/m³4 hours		LC50 Inhalation Gas.	Rat		4 hours
LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LD50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 OralRat39000 mg/m³4 hours		LD50 Dermal	Rabbit	1 mL/kg	-
LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LD50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 OralRat39000 mg/m³4 hours		LD50 Intraperitoneal	Guinea pig	930 mg/kg	-
LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 OralRat39000 mg/m³4 hours		LD50 Intraperitoneal	Mouse		-
LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat12300 uL/kg-LC50 Inhalation VaporRat12300 uL/kg-LC50 Inhalation VaporRat12300 uL/kg-		LD50 Intraperitoneal	Mouse		-
LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 OralMouse12750 mg/kg-		LD50 Intraperitoneal	Rabbit	1540 mg/kg	-
LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat12300 uL/kg-LC50 Inhalation VaporRabbit12300 uL/kg-		LD50 Intraperitoneal	Rabbit	1540 mg/kg	-
LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat12300 uL/kg-LC50 Inhalation VaporRabbit12300 uL/kg-		LD50 Intraperitoneal	Rat	1130 mg/kg	-
LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat12300 uL/kg-LD50 DermalRabbit12300 uL/kg-LD50 OralMouse12750 mg/kg-		LD50 Intraperitoneal	Rat		-
LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat12300 uL/kg-LD50 DermalRabbit12300 uL/kg-LD50 OralMouse12750 mg/kg-		LD50 Oral	Mouse	1400 mg/kg	-
LD50 SubcutaneousRat2170 mg/kg-cumeneLC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat12300 uL/kg-LD50 DermalRabbit12750 mg/kg-		LD50 Oral	Rat	1800 mg/kg	-
cumeneLC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 OralMouse12750 mg/kg-		LD50 Oral	Rat	1620 uL/kg	-
cumeneLC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 OralMouse12750 mg/kg-		LD50 Subcutaneous	Rat	2170 mg/kg	-
LC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 OralMouse12750 mg/kg-	cumene	LC50 Inhalation Vapor	Mouse	15300 mg/m ³	2 hours
LC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 OralMouse12750 mg/kg-		LC50 Inhalation Vapor	Mouse	10 g/m³ _	7 hours
LC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-LD50 OralMouse12750 mg/kg-		LC50 Inhalation Vapor	Mouse	10000 mg/m³	7 hours
LD50 Oral Mouse 12750 mg/kg -		LC50 Inhalation Vapor	Rat		4 hours
		LD50 Dermal	Rabbit	12300 uL/kg	-
LD50 Oral Rat 2.9 g/kg -		LD50 Oral	Mouse		-
		LD50 Oral	Rat	2.9 g/kg	-
LD50 Oral Rat 1400 mg/kg -		LD50 Oral	Rat		-

Conclusion/Summary : Not available.

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
n-butyl acetate	Eyes - Moderate irritant	Rabbit	-	100 mg	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500 mg	-
Reaction mass of ethylbenzene and xylene	Eyes - Mild irritant	Rabbit	-	87 mg	-
	Eyes - Severe irritant	Rabbit	-	24 hours 5 mg	-
	Skin - Mild irritant	Rat	-	8 hours 60 UI	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500 mg	-
	Skin - Moderate irritant	Rabbit	-	100 %	-
4-methylpentan-2-one	Eyes - Moderate irritant	Rabbit	-	24 hours 100 Ul	-
	Eyes - Severe irritant	Rabbit	-	40 mg	-
	Skin - Mild irritant	Rabbit	-	24 hours 500	-
Date of issue/Date of revision	: 1-10-2022	Versi	on :1		
Date of previous issue	: No previous validation	14/23	1		AkzoNobel

SECTION 11: Toxicological information

is a manual so state	Chin Mild invitant	Debbit		mg	
isopropyl acetate	Skin - Mild irritant	Rabbit	-	24 hours 500 mg	-
4-morpholinecarbaldehyde	Eyes - Mild irritant	Rabbit	-	24 hours 500	-
	Skin - Mild irritant	Rabbit	-	mg 24 hours 500	-
				mg	
cyclohexanone	Eyes - Severe irritant	Rabbit	-	24 hours 250 ug	-
	Eyes - Severe irritant	Rabbit	-	20 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
cumene	Eyes - Mild irritant	Rabbit	-	24 hours 500 mg	-
	Eyes - Mild irritant	Rabbit	-	86 mg	-
	Skin - Mild irritant	Rabbit	-	24 hours 10	-
	Skin - Moderate irritant	Rabbit	_	mg 24 hours 100	_
				mg	
Conclusion/Summary	: Not available.	L	•	•	
Sensitization					

Conclusion/Summary	: Not available.
Mutagenicity	
Conclusion/Summary	: Not available.
Carcinogenicity	
Conclusion/Summary	: Not available.
Reproductive toxicity	
Conclusion/Summary	: Not available.
Teratogenicity	
Conclusion/Summary	: Not available.
.	

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
n-butyl acetate	Category 3	-	Narcotic effects
2-methoxy-1-methylethyl acetate	Category 3	-	Narcotic effects
Reaction mass of ethylbenzene and xylene	Category 3	-	Respiratory tract irritation
4-methylpentan-2-one	Category 3	-	Narcotic effects
ethyl acetate	Category 3	-	Narcotic effects
isopropyl acetate	Category 3	-	Narcotic effects
methyl methacrylate	Category 3	-	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Reaction mass of ethylbenzene and xylene	Category 2	-	-

Aspiration hazard

Product/ingredient name	Result
Reaction mass of ethylbenzene and xylene	ASPIRATION HAZARD - Category 1

Information on the likely : Not available. routes of exposure



SECTION 11: Toxicological information

Potential acute health effects				
Eye contact	:	Causes serious eye irritation.		
Inhalation	:	Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness.		
Skin contact	:	Defatting to the skin. May cause skin dryness and irritation.		
Ingestion	:	Can cause central nervous system (CNS) depression.		

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation dryness cracking
Ingestion	: No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure		
Potential immediate effects	:	Not available.
Potential delayed effects	:	Not available.
<u>Long term exposure</u>		
Potential immediate effects	:	Not available.
Potential delayed effects	:	Not available.
Potential chronic health effe	ect	<u>s</u>
Not available.		
Conclusion/Summary	:	Not available.
General	:	Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis.
Carcinogenicity	:	Suspected of causing cancer. Risk of cancer depends on duration and level of exposure.
Mutagenicity	:	No known significant effects or critical hazards.
Reproductive toxicity	:	No known significant effects or critical hazards.
Other information	:	Not available.



SECTION 12: Ecological information

12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is not classified as hazardous to the environment, but contains substance(s) hazardous to the environment. See section 3 for details.

Product/ingredient name	Result	Species	Exposur
n-butyl acetate	Acute LC50 32 mg/l Marine water	Crustaceans - Artemia salina	48 hours
	Acute LC50 100000 µg/l Fresh water	Fish - Lepomis macrochirus	96 hours
	Acute LC50 18000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 185000 µg/l Marine water	Fish - Menidia beryllina	96 hours
	Acute LC50 62000 µg/l Fresh water	Fish - Danio rerio	96 hours
Reaction mass of ethylbenzene and xylene	Acute LC50 13400 µg/l Fresh water	Fish - Pimephales promelas	96 hours
4-methylpentan-2-one	Acute LC50 505000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
<i>.</i>	Acute LC50 540000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 537000 µg/l Fresh water	Fish - Pimephales promelas - Juvenile (Fledgling, Hatchling,	96 hours
		Weanling)	
	Chronic NOEC 78 mg/l Fresh water Chronic NOEC 168 mg/l Fresh water	Daphnia - Daphnia magna Fish - Pimephales promelas - Embryo	21 days 33 days
ethyl acetate	Acute EC50 2500000 µg/l Fresh water	Algae - Selenastrum sp.	96 hours
,	Acute LC50 1600000 µg/l Fresh water	Crustaceans - Asellus aquaticus	48 hours
	Acute LC50 750000 µg/l Fresh water	Crustaceans - Gammarus pulex	48 hours
	Acute LC50 175000 µg/l Fresh water	Daphnia - Daphnia cucullata	48 hours
	Acute LC50 154000 µg/l Fresh water	Daphnia - Daphnia cucullata	48 hours
	Acute LC50 560000 µg/l Fresh water	Daphnia - Daphnia magna	48 hours
	Acute LC50 230000 µg/l Fresh water	Daphnia - Daphnia pulex	48 hours
	Acute LC50 295000 µg/l Fresh water	Daphnia - Daphnia pulex	48 hours
	Acute LC50 230000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 212500 µg/l Fresh water	Fish - Heteropneustes fossilis	96 hours
	Acute LC50 484000 µg/l Fresh water	Fish - Oncorhynchus mykiss -	96 hours
	Acute LC30 464000 µg/i Fresh water	Juvenile (Fledgling, Hatchling, Weanling)	90 110015
	Acute LC50 425300 µg/l Fresh water	Fish - Oncorhynchus mykiss - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Chronic NOEC 12 mg/l Fresh water	Daphnia - Daphnia magna	21 days
	Chronic NOEC 2400 µg/l Fresh water	Daphnia - Daphnia magna	21 days
	Chronic NOEC 75.6 mg/l Fresh water	Fish - Pimephales promelas - Embryo	32 days
sopropyl acetate	Acute LC50 110 mg/l Marine water	Crustaceans - Artemia salina	48 hours
nethyl methacrylate	Acute LC50 191000 µg/l Fresh water	Fish - Lepomis macrochirus - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Acute LC50 159100 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 160200 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 150000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours
	Acute LC50 130000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours
cyclohexanone	Acute EC50 32.9 mg/l Fresh water	Algae - Chlamydomonas reinhardtii - Exponential growth phase	72 hours
	Acute LC50 630000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 527000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 732000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
cumene	Acute EC50 2600 µg/l Fresh water	Algae - Pseudokirchneriella	72 hours
te of issue/Date of revision	: 1-10-2022	Version :1	
te of previous issue	: No previous validation	17/23 A	czoNob

SECTION 12: Ecological information					
	Acute EC50 7.4 mg/l Marine water	subcapitata Crustaceans - Artemia sp Nauplii	48 hours		
	Acute EC50 7.5 mg/l Marine water	Crustaceans - Artemia sp Nauplii	48 hours		
	Acute EC50 10.6 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours		
	Acute EC50 10.6 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours		
	Acute EC50 11.2 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours		
	Acute LC50 7.4 mg/l Marine water	Crustaceans - Artemia sp Nauplii	48 hours		
	Acute LC50 8 mg/l Marine water	Crustaceans - Artemia sp Nauplii	48 hours		
	Acute LC50 20.3 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours		
	Acute LC50 20.3 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours		
	Acute LC50 6320 µg/l Fresh water	Fish - Pimephales promelas	96 hours		
	Acute LC50 5100 µg/l Fresh water	Fish - Poecilia reticulata	96 hours		
	Acute LC50 2700 µg/l Fresh water	Fish - Oncorhynchus mykiss	96 hours		

Conclusion/Summary

: Not available.

12.2 Persistence and degradability

Conclusion/Summary : Not available.

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
n-butyl acetate	2.3	-	low
2-methoxy-1-methylethyl acetate	1.2	-	low
Reaction mass of ethylbenzene and xylene	3.12	8.1 to 25.9	low
4-methylpentan-2-one	1.9	-	low
ethyl acetate	0.68	30	low
isopropyl acetate	1.3	-	low
methyl methacrylate	1.38	-	low
4-morpholinecarbaldehyde	-	<1.9	low
cyclohexanone	0.86	-	low
cumene	3.55	35.48	low

12.4 Mobility in soil

Soil/water partition coefficient (Koc)		Not available.
Mobility	:	Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.



SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

<u>Product</u>	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
Disposal considerations	 Do not allow to enter drains or watercourses. Dispose of according to all federal, state and local applicable regulations. If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned. For further information, contact your local waste authority.

European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

Waste code	Waste designation			
EWC 08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances			
Packaging				
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.			
Disposal considerations	 Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions. 			
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.			

SECTION 14: Transport information

	ADR/RID	IMDG		ΙΑΤΑ
14.1 UN number	UN1263	UN1263	UN1263	
14.2 UN proper shipping name	PAINT	PAINT	PAINT	
14.3 Transport hazard class(es)	3	3	3	
14.4 Packing group				
Date of issue/Date of re	 vision : 1-10-202	22 V	Version : 1	
Date of previous issue	: No previ	ous validation 1	9/23	AkzoNobel

SECTION 14: T	ranspo	ort	information		
14.5 Environmental hazards	No.			No.	No.
Additional informat	ion				
ADR/RID		:		ception This class 3 viscous liqu 50 L according to 2.2.3.1.5.1.	id is not subject to regulation in
IMDG		:		l ules F-E, _S-E_ <u>ception</u> This class 3 viscous liqu 50 L according to 2.3.2.5.	id is not subject to regulation in
14.6 Special precau user	tions for	:			ort in closed containers that are g the product know what to do in
14.7 Transport in bu according to IMO instruments	Ilk	:	Not applicable.		
SECTION 15: F	Regulat	or	y information)	
EU Regulation (EC)	No. 1907	/20	-	egislation specific for the subs	stance or mixture

	<u>Annex XIV</u>			
	None of the components ar	e listed.		
	Substances of very high	<u>concern</u>		
	None of the components ar	e listed.		
	Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	: Not applicable.		
Ω	Other EU regulations			
	VOC		ective 2004/42/EC on VOC apply to this pro echnical data sheet for further information.	duct. Refer to the
	VOC for Ready-for-Use Mixture	: Not applicable.		
	Industrial emissions (integrated pollution prevention and control) - Air	: Not listed		
	Industrial emissions (integrated pollution prevention and control) - Water	: Not listed		
	Ozone depleting substanc	<u>es (1005/2009/EU)</u>		
	Not listed.			
	Prior Informed Consent (P Not listed.	IC) (649/2012/EU)		
	<u>Seveso Directive</u>			
Da	te of issue/Date of revision	: 1-10-2022	Version : 1	

Date of previous issue



SECTION 15: Regulatory information

This product is controlled under the Seveso Directive.

Danger criteria

Category

FUU	

1.50			
National regulations			
Industrial use	: The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.		
Social Security Code, Articles L 461-1 to L 461-7	: n-butyl acetate Reaction mass of ethylbenzene and xylene 4-methylpentan-2-one ethyl acetate isopropyl acetate methyl methacrylate cyclohexanone cumene	RG 84 RG 4bis, RG 84 RG 84 RG 84 RG 84 RG 82 RG 84 RG 84	
Reinforced medical surveillance	: Decree n ° 2012-135 of January 30, 2012 relating to the organization of occupational medicine: not applicable		
International regulations			
Chemical Weapon Convention	on List Schedules I, II & III Chemicals		
Not listed.			
Montreal Protocol			
Not listed.			
Stockholm Convention on P Not listed.	ersistent Organic Pollutants		
Rotterdam Convention on P Not listed.	rior Informed Consent (PIC)		
UNECE Aarhus Protocol on	POPs and Heavy Metals		
Not listed.			
Inventory list			
Europe	: Not determined.		
5.2 Chemical Safety Assessment	: No Chemical Safety Assessment has been carried	out.	
SECTION 16: Other in	formation		
Indicates information that has a second s	as changed from previously issued version.		

Abbreviations and acronyms	 ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number SGG = Segregation Group vPvB = Very Persistent and Very Bioaccumulative
Data afia ana /Data af ransia ia r	Naming 14

Date of issue/Date of revision	: 1-10-2022	Version : 1	
Date of previous issue	: No previous validation	21/23	AkzoNobel

SECTION 16: Other	r information		
Procedure used to derive	the classification acc	cording to Regulation	n (EC) No. 1272/2008 [CLP/GHS]
	Classification		Justification
Flam. Liq. 3, H226 Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H336			On basis of test data Calculation method Calculation method Calculation method
Full text of abbreviated H	<u>statements</u>		
H225 H226 H304 H312 H315 H317 H319 H332 H335 H336 H351 H373 H411 H412 EUH066		Harmful in contact w Causes skin irritation May cause an allerg Causes serious eye Harmful if inhaled. May cause respirato May cause drowsine Suspected of causin May cause damage exposure. Toxic to aquatic life Harmful to aquatic li	d vapor. owed and enters airways. /ith skin. n. ic skin reaction. irritation. ory irritation. ess or dizziness.
Full text of classifications	[CLP/GHS]		, , , ,
Acute Tox. 4 Aquatic Chronic 2 Aquatic Chronic 3 Asp. Tox. 1 Carc. 2 Eye Irrit. 2 Flam. Liq. 2 Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1 STOT RE 2 STOT SE 3		AQUATIC HAZARD ASPIRATION HAZA CARCINOGENICIT SERIOUS EYE DAM FLAMMABLE LIQUI FLAMMABLE LIQUI SKIN CORROSION SKIN SENSITIZATIO SPECIFIC TARGET EXPOSURE) - Cate	(LONG-TERM) - Category 2 (LONG-TERM) - Category 3 (RD - Category 1 Y - Category 2 MAGE/ EYE IRRITATION - Category 2 DS - Category 2 DS - Category 3 /IRRITATION - Category 2 ON - Category 1 ORGAN TOXICITY (REPEATED
Date of printing Date of issue/ Date of revision Date of previous issue Version Unique ID	: 1 October 2022 : 1 October 2022 : No previous va : 1 :	2	
Notice to reader			

Notice to reader

FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are

Date of issue/Date of revision	: 1-10-2022	Version :1	
Date of previous issue	: No previous validation	22/23	A



SECTION 16: Other information

subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.

